Pancreatic Cancer Research

ResearcherLMU KlinikumActive in the last 2 years

Stephan Krüger

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4138-9863; OpenAlex author ID A5045048264. Sources: OpenAlex.

Their work

Papers
35 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
107
Papers, trials and grants by year

2014: 6 papers · 2015: 2 papers · 2016: 3 papers · 2017: 5 papers · 2018: 4 papers · 2019: none · 2020: 5 papers · 2021: 4 papers · 2022: 1 paper · 2023: 3 papers · 2024: none · 2025: 2 papers

Papers 35

  1. PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer. Co-author DOI 10.1038/s41586-025-09017-8↗
  2. Tertiary Lymphoid Structures in Pancreatic Cancer are Structurally Homologous, Share Gene Expression Patterns and B-cell Clones with Secondary Lymphoid Organs,… Co-author DOI 10.1158/2326-6066.cir-24-0299↗
  3. Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison … Co-author DOI 10.1007/s00432-022-04112-z↗
  4. Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrospective Cohort Study. First author DOI 10.1159/000528722↗
  5. Exploring Pain, Quality of Life, and Emotional Well-Being in Patients with Advanced Pancreatic Cancer Practicing Spiritual Meditation: A Pilot Study. Co-author DOI 10.1159/000529865↗
  6. Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 stu… Co-author DOI 10.1016/j.esmoop.2022.100388↗
  7. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel. First author DOI 10.1007/s12094-021-02620-x↗
  8. Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of… Co-author DOI 10.1016/j.ejca.2020.12.029↗
  9. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma -… Co-author DOI 10.1016/j.ejca.2021.03.036↗
  10. Quantitative Imaging Biomarkers of the Whole Liver Tumor Burden Improve Survival Prediction in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers13225732↗
  11. Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled… Co-author DOI 10.1007/s00432-019-03061-4↗
  12. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  13. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is f… Co-author DOI 10.1016/j.suronc.2020.08.031↗
  14. Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 st… Co-author DOI 10.1038/s41416-020-01029-7↗
  15. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkz060↗
  16. POLE gene hotspot mutations in advanced pancreatic cancer. Co-author DOI 10.1007/s00432-018-2746-x↗
  17. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospect… Co-author DOI 10.1016/j.ejca.2018.02.008↗
  18. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2018.08.009↗
  19. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdy417↗
  20. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study. Co-author DOI 10.1016/j.thromres.2017.06.021↗
  21. Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2017.115↗
  22. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Co-author DOI 10.1080/2162402x.2017.1310358↗
  23. Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational resea… Co-author DOI 10.1186/s12885-017-3376-4↗
  24. The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy. Co-author DOI 10.3390/ijms18051094↗
  25. Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2016.03.016↗
  26. Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and… Co-author DOI 10.1038/bjc.2016.355↗
  27. Safety of palliative chemotherapy in advanced pancreatic cancer. First author DOI 10.1080/14740338.2016.1177510↗
  28. Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3. Co-author DOI 10.1007/s13277-014-2885-x↗
  29. Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis fr… Co-author DOI 10.3109/0284186x.2015.1034877↗
  30. ALK expression is absent in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-014-1774-4↗
  31. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK010… Co-author DOI 10.1016/j.ejca.2014.04.023↗
  32. Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult. Co-author DOI 10.1038/bjc.2014.60↗
  33. pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. Co-author DOI 10.1186/1471-2407-14-624↗
  34. Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts. Co-author DOI 10.3748/wjg.v20.i31.10769↗
  35. Long-term progression-free survival in a metastatic pancreatic cancer patient treated with first-line nab-paclitaxel and gemcitabine. Co-author PMID 25398821↗

Closest collaborators

The 25 strongest of 107 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stefan Hubert Boeck · 32 shared papers, 2014–2025 · strength 2.72
  2. Michael Haas · 29 shared papers, 2014–2025 · strength 2.26
  3. Volker Heinemann · 28 shared papers, 2014–2025 · strength 2.18
  4. Steffen Ormanns · 24 shared papers, 2014–2025 · strength 1.98
  5. Christoph Benedikt Westphalen · 15 shared papers, 2016–2023 · strength 1.32
  6. Jens Werner · 11 shared papers, 2016–2025 · strength 1.07
  7. Michael Guenther · 4 shared papers, 2018–2025 · strength 0.51
  8. Stefan Holdenrieder · 5 shared papers, 2015–2023 · strength 0.39
  9. Dominik Paul Modest · 6 shared papers, 2015–2021 · strength 0.38
  10. Jan Goesta D’Haese · 5 shared papers, 2018–2020 · strength 0.38
  11. Leonie Gebauer · 3 shared papers, 2020–2023 · strength 0.35
  12. Julia V. Mayerle · 4 shared papers, 2018–2020 · strength 0.32
  13. Christiane J. Bruns · 3 shared papers, 2016–2025 · strength 0.31
  14. Jens Thomas Siveke · 5 shared papers, 2014–2022 · strength 0.31
  15. Sebastian Kobold · 3 shared papers, 2020–2022 · strength 0.30
  16. Danmei Zhang · 2 shared papers, 2023 · strength 0.30
  17. Lena Weiss · 2 shared papers, 2023 · strength 0.30
  18. Klara Dorman · 2 shared papers, 2023 · strength 0.30
  19. Lisa Miller‐Phillips · 2 shared papers, 2022–2025 · strength 0.29
  20. Falk Roeder · 4 shared papers, 2016–2020 · strength 0.27
  21. Marianne Sinn · 2 shared papers, 2021–2022 · strength 0.23
  22. Christine Eggers · 1 shared paper, 2023 · strength 0.22
  23. Waldemar H. Uhl · 1 shared paper, 2023 · strength 0.22
  24. Karin Meißner · 1 shared paper, 2023 · strength 0.22
  25. Thomas Theodor Werner Seufferlein · 2 shared papers, 2021–2022 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.